




The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 158% points. The greatest weakness of Crescent Biopharma INC is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 373%, being 135% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	162,528
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,951
Liabilities, Non-Current	2,819
Other Assets	4,619
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,497
Other Revenues	0
Property and Equipment	823
Research and Development	47,029
Selling, General and Administrative Expense	14,360

Output Variable	Value in 1000 USD
Assets	167,970
Liabilities	13,769
Expenses	61,389
Revenues	0
Stockholders Equity	154,201
Net Income	-57,892
Comprehensive Net Income	-57,892
BaseVar	123,313
ECR before LimitedLiability	306%
Economic Capital Ratio	373%